La Jolla Pharmaceutical (NASDAQ:LJPC) Stock Rating Upgraded by BidaskClub

BidaskClub upgraded shares of La Jolla Pharmaceutical (NASDAQ:LJPC) from a strong sell rating to a sell rating in a research report report published on Saturday, BidAskClub reports.

Other analysts also recently issued research reports about the stock. ValuEngine upgraded shares of La Jolla Pharmaceutical from a sell rating to a hold rating in a report on Thursday, August 1st. HC Wainwright lifted their target price on shares of La Jolla Pharmaceutical from $25.00 to $27.00 and gave the company a positive rating in a report on Thursday, June 6th. Chardan Capital set a $20.00 target price on shares of La Jolla Pharmaceutical and gave the company a buy rating in a report on Monday, June 24th. Finally, Zacks Investment Research downgraded shares of La Jolla Pharmaceutical from a buy rating to a hold rating in a report on Thursday, August 8th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. The company has a consensus rating of Hold and an average price target of $15.50.

La Jolla Pharmaceutical stock opened at $9.96 on Friday. La Jolla Pharmaceutical has a fifty-two week low of $5.01 and a fifty-two week high of $24.53. The firm has a 50 day moving average price of $9.01 and a 200 day moving average price of $7.60. The company has a market capitalization of $255.83 million, a PE ratio of -1.27 and a beta of 2.22.



La Jolla Pharmaceutical (NASDAQ:LJPC) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.12) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($1.12). La Jolla Pharmaceutical had a negative net margin of 891.53% and a negative return on equity of 715.12%. The firm had revenue of $5.70 million during the quarter, compared to the consensus estimate of $5.76 million. As a group, research analysts predict that La Jolla Pharmaceutical will post -4.35 earnings per share for the current year.

A number of hedge funds have recently modified their holdings of the business. Bank of Montreal Can boosted its position in La Jolla Pharmaceutical by 27.2% in the 2nd quarter. Bank of Montreal Can now owns 7,043 shares of the biopharmaceutical company’s stock valued at $65,000 after buying an additional 1,506 shares during the period. Northern Trust Corp boosted its position in La Jolla Pharmaceutical by 0.7% in the 2nd quarter. Northern Trust Corp now owns 276,154 shares of the biopharmaceutical company’s stock valued at $2,555,000 after buying an additional 1,880 shares during the period. Parametric Portfolio Associates LLC boosted its position in La Jolla Pharmaceutical by 25.5% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 13,236 shares of the biopharmaceutical company’s stock valued at $122,000 after buying an additional 2,693 shares during the period. Morgan Stanley boosted its position in La Jolla Pharmaceutical by 0.7% in the 2nd quarter. Morgan Stanley now owns 420,862 shares of the biopharmaceutical company’s stock valued at $3,893,000 after buying an additional 2,780 shares during the period. Finally, BNP Paribas Arbitrage SA boosted its position in La Jolla Pharmaceutical by 63,657.1% in the 1st quarter. BNP Paribas Arbitrage SA now owns 4,463 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 4,456 shares during the period. 94.13% of the stock is owned by institutional investors.

La Jolla Pharmaceutical Company Profile

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock.

See Also: What are the benefits of buying treasury bonds?

Analyst Recommendations for La Jolla Pharmaceutical (NASDAQ:LJPC)

Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.